Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.52 |
| ▸ | USP2 | O75604 | 9/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096235 | 0.88 | GSK3B (0.61) | GSK3BMTNR1AMTNR1BKDM4E | |
| SCHEMBL2404679 | 0.86 | GSK3B (0.66) | GSK3B | |
| SCHEMBL5105275 | 0.83 | GSK3B (0.61) | GSK3BTP53 | |
| SCHEMBL2402713 | 0.81 | GSK3B (0.76) | GSK3BCYP3A4HSD17B10ALDH1A1MAPK1 | |
| SCHEMBL5098653 | 0.79 | GSK3B (0.58) | GSK3BMTNR1AMTNR1B | |
| SCHEMBL2403904 | 0.78 | GSK3B (0.75) | GSK3BCYP2D6 | |
| SCHEMBL5104869 | 0.78 | GSK3B (0.60) | GSK3B | |
| SCHEMBL2403556 | 0.77 | GSK3B (0.70) | GSK3BLMNA | |
| SCHEMBL7990994 | 0.76 | HTR2A (0.52) | CYP1A2CYP3A4CYP2C19CLK4CYP2D6 | |
| SCHEMBL2405106 | 0.75 | GSK3B (0.72) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885CYP1A2 727/4885CYP3A4 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.